Nueva inmunoterapia contra el mieloma
Llega a España un innovador tratamiento inmunoterápico para combatir el mieloma múltiple
Anonymous
Spain now has access to belantamab mafodotina, a new immunotherapy drug for multiple myeloma patients whose cancer has returned after initial treatment. Levante-EMV reports the drug works like a biological Trojan horse—it sneaks into cancer cells and releases a deadly molecule that kills them from the inside.
How the Drug Attacks Cancer Cells
Belantamab mafodotina is an immunotherapy that targets a protein found on multiple myeloma cells. The drug binds to this protein and enters the cell. Once inside, it releases a toxic payload that destroys the cancer cell from within, La Provincia explains.
Why Relapsed Myeloma Needs New Options
Multiple myeloma often returns after initial treatment. Patients need new drugs when their cancer becomes resistant to earlier therapies. Belantamab mafodotina offers a fresh approach for these difficult cases, La Opinión de Málaga reports.
Spain Joins Growing List of Countries with Access
Multiple European nations have already approved belantamab mafodotina for cancer treatment. Spain's approval marks an expansion of immunotherapy options across the region. Patients in Madrid, Barcelona, and other major cities can now access this new drug, El Periódico de Extremadura states.
Sentiment
NeutralNEGATIVENEUTRALPOSITIVE
Publishers
13
Articles
0
Reach
13
A
AnonymousAuthor
